The NF-κB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs

Leukemia and Lymphoma

Volumn 49, Issue 10, 2008, Pages 1982-1994

  Vega, Mario I ^a,b   Martinez Paniagua, Melissa ^a,b   Jazirehi, Ali ^a   Huerta Yepez, Sara ^a,c   Umezawa, Kazuo ^d   Martinez Maza, Otoniel ^a,e   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Hospital de Infectologia   (Mexico)

^c HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^d KEIO UNIVERSITY   (Japan)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS lymphoma; Apoptosis; Bortezomib; CD20; DHMEQ; Rituximab

Indexed keywords

BORTEZOMIB; CISPLATIN; DEHYDROXYMETHYLEPOXYQUINOMICIN; ETOPOSIDE; PACLITAXEL; PROTEASOME INHIBITOR; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BORONIC ACID DERIVATIVE; CYCLOHEXANONE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; PYRAZINE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APOPTOSIS; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CLONE; CELL SURFACE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIZATION; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; WILD TYPE; ARTICLE; B CELL LYMPHOMA; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; BORONIC ACIDS; CELL LINE, TUMOR; CYCLOHEXANONES; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, B-CELL; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES;

EID: 55049126696     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802357071     Document Type: Conference Paper

References (43)

1. Reff, M. E., Carner, K., Chambers, K. S., Chinn, P. C., Leonard, J. E. Raab, R. et al. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 83, pp. 435-445.
2. Grillo-Lopez, A. J. (2002) Monoclonal antibody therapy for B-cell lymphoma. Int J Hematol, 76, pp. 385-393.
3. Jazirehi, A. R. and Bonavida, B. (2005) Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: Implications in chemosensitization and therapeutic intervention. Oncogene, 24, pp. 2121-2143.
4. McLaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczman, M. S. Williams, M. E. et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol, 16, pp. 2825-2833.
5. Mounier, N., Spina, M. and Gisselbrecht, C. (2007) Modern management of non-Hodgkin lymphoma in HIV-infected patients. Br J Haematol, 136, pp. 685-698.
6. Noy, A. (2007) Update on HIV lymphoma. Curr Oncol Rep, 9, pp. 384-390.
7. Behler, C. M. and Kaplan, L. D. (2006) Advances in the management of HIV-related non-Hodgkin lymphoma. Curr Opin Oncol, 18, pp. 437-443.
8. Spina, M. and Tirelli, U. (2005) Rituximab for HIV-associated lymphoma: weighing the benefits and risks. Curr Opin Oncol, 17, pp. 462-465.
9. Treon, S. P., Shima, Y., Preffer, F. I., Doss, D. S., Ellman, L. Schlossman, R. L. et al. (1999) Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy. Semin Oncol, 14:5, pp. 97-106.
10. Multani, P. S. and Grossbard, M. L. (1998) Monoclonal antibody-based therapies for hematologic malignancies. J Clin Oncol, 16, pp. 3691-3710.
11. Berinstein, N. L., Grillo-Lopez, A. J., White, C. A., ce-Bruckler, I., Maloney, D. Czuczman, M. et al. (1998) Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol, 9, pp. 995-1001.
12. Grossbard, M. L., Press, O. W., Appelbaum, F. R., Bernstein, I. D. and Nadler, L. M. (1992) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood, 80, pp. 863-878.
13. Bjorge, L., Jensen, T. S. and Matre, R. (1996) Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line. Cancer Immunol Immunother, 42, pp. 185-192.
14. Schmitt, C. A., Schwaeble, W., Wittig, B. M., Meyer zum Buschenfelde, K H and Dippold, W. G. (1999) Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours. Eur J Cancer, 35, pp. 117-124.
15. Villunger, A., Egle, A., Marschitz, I., Kos, M., Bock, G. Ludwig, H. et al. (1997) Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance. Blood, 90, pp. 12-20.
16. Vega, M. I., Huerta-Yepaz, S., Garban, H., Jazirehi, A., Emmanouilides, C. and Bonavida, B. (2004) Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance. Oncogene, 23, pp. 3530-3540.
17. Jazirehi, A. R., Vega, M. I. and Bonavida, B. (2007) Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res, 67, pp. 1270-1281.
18. Umezawa, K. (2006) Inhibition of tumor growth by NF-κB inhibitors. Cancer Sci, 97, pp. 990-995.
19. Pedersen, I. M., Buhl, A. M., Klausen, P., Geisler, C. H. and Jurlander, J. (2002) The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood, 99, pp. 1314-1319.
20. Alas, S. and Bonavida, B. (2001) Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res, 61, pp. 5137-5144.
21. Tzung, S. P., Kim, K. M., Basanez, G., Giedt, C. D., Simon, J. Zimmerberg, J. et al. (2001) Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol, 3, pp. 183-191.
22. Czuczman, M. S., Fallon, A., Mohr, A., Stewart, C., Bernstein, Z. P. McCarthy, P. et al. (2002) Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol, 1, pp. 36-40.
23. Davis, T. A., Grillo-Lopez, A. J., White, C. A., McLaughlin, P., Czuczman, M. S. Link, B. K. et al. (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol, 18, pp. 3135-3143.
24. Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N. and Bonavida, B. (1997) Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm, 12, pp. 177-186.
25. Shan, D., Ledbetter, J. A. and Press, O. W. (2000) Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother, 48, pp. 673-683.
26. Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H. Ma, D. et al. (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood, 92, pp. 1927-1932.
27. Maloney, D. G., Grillo-Lopez, A. J., White, C. A., Bodkin, D., Schilder, R. J. Neidhart, J. A. et al. (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 90, pp. 2188-2195.
28. Maloney, D. G., Smith, B. and Rose, A. (2002) Rituximab: Mechanism of action and resistance. Semin Oncol, 1, pp. 2-9.
29. Pickartz, T., Ringel, F., Wedde, M., Renz, H., Klein, A. von, N. N. et al. (2001) Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab. Exp Hematol, 12, pp. 1410-1416.
30. Brasoveanu, L. I., Altomonte, M., Gloghini, A., Fonsatti, E., Coral, S. Gasparollo, A. et al. (1995) Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity. Int J Cancer, 61, pp. 548-556.
31. Varsano, S., Rashkovsky, L., Shapiro, H. and Radnay, J. (1998) Cytokines modulate expression of cell-membrane complement inhibitory proteins in human lung cancer cell lines. Am J Respir Cell Mol Biol, 19, pp. 522-529.
32. Jarvis, G. A., Li, J., Hakulinen, J., Brady, K. A., Nordling, S. Dahiya, R. et al. (1997) Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer, 71, pp. 1049-1055.
33. Treon, S. P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D. Schlossman, R. et al. (2001) Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-Cell malignancies. J Immunother, 24, pp. 263-271.
34. Jilani, I., O'Brien, S., Manshuri, T., Thomas, D. A., Thomazy, V. A. Imam, M. et al. (2003) Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood, 102, pp. 3514-3520.
35. Weng, W. K. and Levy, R. (2001) Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood, 98, pp. 1352-1357.
36. Bannerji, R., Kitada, S., Flinn, I. W., Pearson, M., Young, D. Reed, J. C. et al. (2003) Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: Relationship to in vivo rituximab resistance. J Clin Oncol, 21, pp. 1466-1471.
37. Cragg, M. S., Morgan, S. M., Chan, H. T., Morgan, B. P., Filatov, A. V. Johnson, P. W. et al. (2003) Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood, 101, pp. 1045-1052.
38. Semac, I., Palomba, C., Kulangara, K., Klages, N., Echten-Deckert, G. Borisch, B. et al. (2003) Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res, 63, pp. 534-540.
39. Bezombes, C., Grazide, S., Garret, C., Fabre, C., Quillet-Mary, A. Muller, S. et al. (2004) Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood, 104, pp. 1166-1173.
40. Deans, J. P., Li, H. and Polyak, M. J. (2002) CD20-mediated apoptosis: signalling through lipid rafts. Immunology, 107, pp. 176-182.
41. Jazirehi, A. R., Bezombes, C., Laurant, G., Libra, M. and Bonavida, B. (2006) Characteristics of rituximab-resistant B-NHL clones: Deficiencies in rituximab-mediated changes in lipid raft micro-domains and cell signaling. Proc AACR, 47, p. 4657.
42. Alas, S., Emmanouilides, C. and Bonavida, B. (2001) Inhibition of interleukin 10 by rituximab results in down-regulation of Bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res, 3, pp. 709-723.
43. Alas, S. and Bonavida, B. (2003) Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res, 1, pp. 316-326.